Sana Biotechnology Inc (SANA)
2.61
+0.26
(+11.06%)
USD |
NASDAQ |
Nov 22, 16:00
2.68
+0.07
(+2.68%)
After-Hours: 20:00
Sana Biotechnology Enterprise Value: 383.72M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 383.72M |
| November 21, 2024 | 325.67M |
| November 20, 2024 | 365.86M |
| November 19, 2024 | 327.91M |
| November 18, 2024 | 323.44M |
| November 15, 2024 | 341.30M |
| November 14, 2024 | 379.26M |
| November 13, 2024 | 394.89M |
| November 12, 2024 | 435.08M |
| November 11, 2024 | 446.24M |
| November 08, 2024 | 471.92M |
| November 07, 2024 | 493.13M |
| November 06, 2024 | 562.34M |
| November 05, 2024 | 557.87M |
| November 04, 2024 | 640.48M |
| November 01, 2024 | 618.16M |
| October 31, 2024 | 582.43M |
| October 30, 2024 | 617.57M |
| October 29, 2024 | 644.34M |
| October 28, 2024 | 675.58M |
| October 25, 2024 | 639.88M |
| October 24, 2024 | 651.03M |
| October 23, 2024 | 646.57M |
| October 22, 2024 | 671.11M |
| October 21, 2024 | 677.81M |
| Date | Value |
|---|---|
| October 18, 2024 | 744.74M |
| October 17, 2024 | 706.81M |
| October 16, 2024 | 744.74M |
| October 15, 2024 | 724.66M |
| October 14, 2024 | 695.66M |
| October 11, 2024 | 691.19M |
| October 10, 2024 | 655.50M |
| October 09, 2024 | 691.19M |
| October 08, 2024 | 711.27M |
| October 07, 2024 | 740.28M |
| October 04, 2024 | 744.74M |
| October 03, 2024 | 749.20M |
| October 02, 2024 | 773.74M |
| October 01, 2024 | 746.97M |
| September 30, 2024 | 729.12M |
| September 27, 2024 | 700.51M |
| September 26, 2024 | 698.29M |
| September 25, 2024 | 584.83M |
| September 24, 2024 | 658.24M |
| September 23, 2024 | 658.24M |
| September 20, 2024 | 693.84M |
| September 19, 2024 | 776.15M |
| September 18, 2024 | 702.74M |
| September 17, 2024 | 704.96M |
| September 16, 2024 | 718.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.67M
Minimum
Dec 27 2022
7.771B
Maximum
Feb 10 2021
1.461B
Average
871.05M
Median
Enterprise Value Benchmarks
| Foghorn Therapeutics Inc | 168.45M |
| Omega Therapeutics Inc | 28.73M |
| Moderna Inc | 8.953B |
| Summit Therapeutics Inc | 13.55B |
| Apellis Pharmaceuticals Inc | 3.883B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -59.92M |
| Total Expenses (Quarterly) | 61.76M |
| EPS Diluted (Quarterly) | -0.25 |
| Earnings Yield | -53.64% |